Wen liang Lv

Wen liang Lv


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
QWQing juan Wu
Qing juan Wu
全孙全梅 孙
全梅 孙
QZQiang Zhang
Qiang Zhang
NWNing Wang
Ning Wang
WLWen liang Lv
Wen liang Lv
DHDong Han
Dong Han
The mechanobiological response mechanism of the fenestrae of liver sinusoidal endothelial cells (LSECs) to the physical stiffness of the extracellular matrix (ECM) remains unclear. We investigated how the mechanical properties of their substrates affect the LSECs’ fenestrae by the nitric oxide (NO)-dependent pathway and how they relate to the progression of hepatic sinus capillarization during liver fibrosis. We detected different stiffnesses of ECM in the progress of liver fibrosis (LF) and developed polyacrylamide hydrogel (PAM) substrates to simulate them. Softer stiffness substrates contributed to LSECs maintaining fenestrae phenotype in vitro. The stiffness of liver fibrosis tissue could be reversed in vivo via treatment with anti-ECM deposition drugs. Similarly, the capillarization of LSECs could be reversed by decreasing the ECM stiffness. Our results also indicate that the NO-dependent pathway plays a key regulatory role in the capillarization of ECM-LSECs. Our study reveals ECM-induced mechanotransduction of capillarized LSECs through a NO-dependent pathway via a previously unrevealed mechanotransduction mechanism. The elucidation of this mechanism may offer precise biomechanics-specific intervention strategies targeting liver fibrosis progression.

15 March 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
DWDongjie Wu
Dongjie Wu
FXFeiyang Xiong
Feiyang Xiong
QRQingzhi Ran
Qingzhi Ran
JLJing Liu
Jing Liu
QWQingjuan Wu
Qingjuan Wu
WLWen liang Lv
Wen liang Lv
Background: Evidence from observational studies suggests that chronic hepatitis B (CHB) is associated with cardiovascular disease (CVD). However, results have been inconsistent and causality remains to be established. We utilized two-sample Mendelian randomization (MR) to investigate potential causal associations between CHB and CVD, including atherosclerosis, coronary heart disease, hypertension, and ischemic stroke.Methods: The analysis was conducted through genome-wide association studies (GWAS), considering chronic hepatitis B as the exposure and cardiovascular disease as the endpoint. The primary method for evaluating causality in this analysis was the inverse-variance weighted (IVW) technique. Additionally, we employed the weighted median, MR-Egger regression, weighted mode, and simple mode methods for supplementary analyses. Finally, heterogeneity tests, sensitivity analyses, and multiple effects analyses were conducted.Results: In a random-effects IVW analysis, we found that genetic susceptibility to chronic hepatitis B was associated with an increased risk of atherosclerosis [OR = 1.048, 95% CI (1.022–1.075), P = 3.08E-04], as well as an increased risk of coronary heart disease [OR = 1.039, 95% CI (1.006–1.072), P = 0.020]. However, it was found to be inversely correlated with ischemic stroke risk [OR = 0.972, 95% CI (0.957–0.988), P = 4.13E-04]. There was no evidence that chronic hepatitis B was associated with hypertension [OR = 1.021, 95% CI (0.994–1.049), P = 0.121].Conclusion: Our research indicates that chronic hepatitis B has a correlation with an elevated risk of developing atherosclerosis and coronary heart disease, while it is associated with a decreased risk of experiencing an ischemic stroke.

5 June 2020 in Trials
Verified
Journal Article
Open access
PDF file
QWQing-Juan Wu
Qing-Juan Wu
WLWen liang Lv
Wen liang Lv
JLJuan-Mei Li
Juan-Mei Li
TZTing-Ting Zhang
Ting-Ting Zhang
WZWen-Hui Zhou
Wen-Hui Zhou
JCJing Chen
Jing Chen
Introduction: Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that a combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better efficacy than conventional antiviral for treatment of CHB. YinQiSanHuang-antiviral decoction (YQSH) is a TCM compound preparation that has shown an effect on anti-hepatitis B virus and on slowing progression of hepatitis B-related liver diseases. To evaluate the efficacy and safety of YQSH combined with entecavir and its preventive effect on hepatitis B cirrhosis, we designed this randomized, double-blind and placebo-controlled trial. The objective is that the combination of YinQiSanHuang-antiviral decoction with entecavir will reduce the annual incidence of liver fibrosis/cirrhosis to 1%. Methods: This is a multicenter, randomized, placebo-controlled, double-blinded trial involving five hospitals. A total of 802 patients are randomly allocated to two groups: the YQSH group (n = 401) or the placebo group (n = 401). The YQSH group receives YQSH with entecavir; the placebo group receives granules of placebo with entecavir. Patients receive treatment for 52 weeks and then are followed up for 52 ± 2 weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are hepatitis B virus DNA negative rate, hepatitis B surface antigen negative rate, hepatitis B e antigen seroconversion rate, liver function (alanine aminotransferase, aspartate aminotransferase , gamma-glutamyl transferase , alkaline phosphatase , serum albumin, and total bilirubin), spleen thickness, evaluation scores of patients’ clinical symptoms, and safety assessment. Outcomes will be assessed at baseline and after treatment. Discussion: Combination therapy could become a trend for treatment of CHB, and this trial expects to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB. Trial registration: Chinese Clinical Trial Registry: ChiCTR1900021521. Registered on 25 February 2019.

14 October 2021 in Trials
Verified
Journal Article
Open access
PDF file
QWQing-Juan Wu
Qing-Juan Wu
WLWen liang Lv
Wen liang Lv
JLJuan-Mei Li
Juan-Mei Li
TZTing-Ting Zhang
Ting-Ting Zhang
WZWen-Hui Zhou
Wen-Hui Zhou
LWLi Wang
Li Wang
Introduction: Hepatitis B-related compensated liver cirrhosis is related to a higher risk of hepatocellular carcinoma, and antiviral therapy is the preferred method. As the pathological mechanisms of liver fibrosis are complex, drugs developed for a single target are difficult to be effective in clinical practice, so there are no chemical drugs or biological drugs with clear efficacy available for clinical application at present. Traditional Chinese medicine is a kind of medical science that has been gradually formed during thousands of years and continuously enriched by the people of all ethnic groups in China. Traditional Chinese medicine shows curative effects in the treatment of liver diseases, especially in the field of liver fibrosis prevention and treatment. This study aims to test the integrative medicine (Chinese medicine plus antiviral therapy) effective on lowing hepatocellular carcinoma risk among patients with hepatitis-related compensated liver cirrhosis. Methods and analysis: This is a multi-center randomized controlled trial, and a total of 5 hospitals and 802 patients will be involved in. All the subjects are randomly allocated to the YinQiSanHuang Jiedu decoction (YQSHD) group (n = 401) or the placebo group (n = 401). The YQSHD group receives YQSHD granule with entecavir (ETV), and the placebo group receives YQSHD placebo with ETV. The treatment period will last for 52 weeks, and the follow-up period for 52 ± 2 weeks. The primary outcome measure is the annual incidence of HCC. Outcomes will be assessed at baseline and after treatment. The objective of this trial is “the integrative of YQSHD with ETV reduce the annual incidence of HCC to 1%.” Ethics and dissemination: The protocol has been approved by the Medical Ethics Committee of Guang’anmen Hospital, China (No.2019-006-KY), and the other centers in the trial will not begin recruiting until the local ethical approval has been obtained. Trial final results will be disseminated via publication. Trial registration: Chinese Clinical Trial Registry ChiCTR1900021532. Registered on February 26, 2019

12 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZYZelin Ye
Zelin Ye
MLMingrui Liu
Mingrui Liu
QWQingjuan Wu
Qingjuan Wu
JWJiuchong Wang
Jiuchong Wang
WLWen liang Lv
Wen liang Lv
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous liver disease involving metabolic dysfunction, inflammatory activity, immune activation, and fibrotic remodeling. Immune-inflammatory biomarkers and immune-related features may support disease characterization, fibrosis assessment, and risk stratification, but the knowledge structure of this subfield remains unclear. This study used bibliometric methods to map the development, contributors, intellectual structure, and emerging trends of immune-inflammatory biomarker and immune-feature research in MASLD/NAFLD. Methods: Publications were retrieved from the Web of Science Core Collection (WoSCC), with Scopus used for cross-database validation. After manual screening and data refinement, 268 WoSCC publications from 2000 to 2025 were retained for primary analysis. CiteSpace and VOSviewer were used to analyze publication trends, contributing countries, institutions, journals, authors, collaboration networks, keyword co-occurrence, keyword bursts, and reference co-citation clusters. Results: Annual publication output increased markedly after 2022. China contributed the largest number of publications, whereas the United States showed the strongest collaborative link strength. Aarhus University was the leading institution, while Henning Grønbæk and Konstantin Kazankov were the leading authors by publication output. Co-citation and keyword analyses indicated that the field is organized around overlapping domains, including systemic inflammatory indices, hepatic inflammation and histologic injury, immune-cell and macrophage-centered features, fibrosis assessment, treatment-response readouts, and prognostic stratification. Recent keyword bursts highlighted oxidative stress, macrophages, pathogenesis, and liver fibrosis. Scopus validation showed broadly consistent temporal and thematic patterns. Discussion: Overall, this subfield is rapidly expanding toward fibrosis-oriented stratification, immune-cell phenotyping, and clinically scalable inflammatory biomarker research.

7 January 2020 in Research Square
Verified
Preprint
Open access
PDF file
QWQing-Juan Wu
Qing-Juan Wu
WLWen liang Lv
Wen liang Lv
JLJuan-Mei Li
Juan-Mei Li
TZTing-Ting Zhang
Ting-Ting Zhang
WZWen-Hui Zhou
Wen-Hui Zhou
JCJing Chen
Jing Chen
Background: Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better clinical efficacy than conventional antiviral for treatment of CHB. YinQiSanHuang-antiviral decoction (YQSH) is a TCM compound preparation used for over thirty years, and has shown its effect on anti-hepatitis B virus and slowing progression of hepatitis B-related liver diseases in a small-scale clinical observation. Until now there is no convincing evidence demonstrating the clinical effectiveness of YQSH in anti-liver cirrhosis and anti-liver cancer. To evaluate the efficacy and safety of YQSH and its preventive effect on hepatitis B cirrhosis, a rigorously designed randomized, double-blind, placebo-controlled clinical trial is needed. Methods: This is a multicenter, randomized, placebo-controlled, double-blinded trial, 5 hospitals involved in. Totally 802 patients are randomly allocated to two groups: the YQSH group (n=401) or the placebo group (n=401). The YQSH group receives YQSH with Entecavir, the placebo group receives granule of placebo with Entecavir. Patients receive treatment for 52 weeks, and then are followed up for 52±2 weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are HBV-DNA negative rate, HBsAg negative rate, HBeAg seroconversion rate, liver function (Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), serum albumin (ALB) and total bilirubin (TBIL)), spleen thickness, evaluation scores of patients’ clinical symptoms and safety assessment. Outcomes will be assessed at baseline and after treatment. Discussion: Combination therapy could become a trendy of treatment of CHB, this trial expecting to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB. Trial registration: ChiCTR1900021521, this protocol was registered in the Chinese Clinical Trial Registry (URL: http://www.chictr.org.cn) on February 25th, 2019. Keywords: chronic hepatitis B, cirrhosis, traditional Chinese medicine, clinical trial, efficacy